Article info
PDFInflammatory bowel disease
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
- Correspondence to:
Dr C S Probert
Bristol Royal Infirmary, Bristol BS2 8HW, UK; c.s.j.probert{at}bristol.ac.uk
Citation
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
Publication history
- Accepted September 21, 2005
- Revised September 21, 2005
- First published September 27, 2005.
Online issue publication
January 09, 2022
Article Versions
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by Gut